Steven Zelenkofske
Director/Board Member at CADRENAL THERAPEUTICS, INC.
Net worth: 24 400 $ as of 2024-03-30
Profile
Steven L.
Zelenkofske is currently the Director & Chief Strategy Officer at DiNAQOR AG and an Independent Director at Cadrenal Therapeutics, Inc. He is also an Associate Professor at Philadelphia College of Osteopathic Medicine and Hershey Medical Center.
In the past, Dr. Zelenkofske held positions such as Senior Director at Novartis Pharmaceuticals Corp., Clinical Director at The Heart Care Group, Chief Medical Officer & Executive Vice President at Achillion Pharmaceuticals, Inc., Chief Medical Officer at Regado Biosciences, Inc., Chief Patient Safety Officer at Cardiac Rhythm Management, VP-Cardiovascular & Thrombosis Medical Unit at Sanofi-Aventis Pharmaceuticals, Chief Medical Officer at uniQure NV, and Chief Medical Officer at SwanBio Therapeutics, Inc.Dr. Zelenkofske obtained his undergraduate and graduate degrees from Emory University and his doctorate from Philadelphia College of Osteopathic Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-06 | 40,000 ( 0.25% ) | 24 400 $ | 2024-03-30 |
Steven Zelenkofske active positions
| Companies | Position | Start |
|---|---|---|
| CADRENAL THERAPEUTICS, INC. | Director/Board Member | 2023-01-18 |
| Philadelphia College of Osteopathic Medicine | Corporate Officer/Principal | - |
| Hershey Medical Center | Corporate Officer/Principal | - |
DiNAQOR AG
 DiNAQOR AG BiotechnologyHealth Technology DiNAQOR AG is a Swiss genetic medicine platform company that focuses on developing innovative solutions for patients with severe, inherited forms of heart disease. The private company is based in Pfäffikon, Switzerland, and has additional presence in Massachusetts and other locations. The company's lead preclinical program, DINA-001, is aimed at treating mybpc3-linked cardiomyopathy. Founded in 2019, the CEO of DiNAQOR is Johannes Holzmeister. | Director/Board Member | 2020-04-30 |
Former positions of Steven Zelenkofske
| Companies | Position | End |
|---|---|---|
| ACHILLION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2020-01-27 |
| UNIQURE N.V. | Chief Tech/Sci/R&D Officer | 2018-08-31 |
Regado Biosciences, Inc.
 Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Chief Tech/Sci/R&D Officer | 2014-10-31 |
| Sanofi-Aventis Pharmaceuticals | Corporate Officer/Principal | 2008-12-31 |
Cardiac Rhythm Management
 Cardiac Rhythm Management Medical SpecialtiesHealth Technology Part of Japan Lifeline Co., Ltd., Cardiac Rhythm Management is a private company that manufactures implantable devices to treat arrhythmias. The company is based in Sylmar, CA. | Corporate Officer/Principal | - |
Training of Steven Zelenkofske
| Emory University | Graduate Degree |
| Philadelphia College of Osteopathic Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| UNIQURE N.V. | Health Technology |
| CADRENAL THERAPEUTICS, INC. | Health Technology |
| Private companies | 8 |
|---|---|
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
Regado Biosciences, Inc.
Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Health Technology |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Cardiac Rhythm Management
Cardiac Rhythm Management Medical SpecialtiesHealth Technology Part of Japan Lifeline Co., Ltd., Cardiac Rhythm Management is a private company that manufactures implantable devices to treat arrhythmias. The company is based in Sylmar, CA. | Health Technology |
| Sanofi-Aventis Pharmaceuticals | |
The Heart Care Group
 The Heart Care Group Medical/Nursing ServicesHealth Services The Heart Care Group is an outpatient cardiac care practice that prioritizes wellbeing and preventative care. The American company offers a new take on cardiac wellness. | Health Services |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Health Technology |
DiNAQOR AG
DiNAQOR AG BiotechnologyHealth Technology DiNAQOR AG is a Swiss genetic medicine platform company that focuses on developing innovative solutions for patients with severe, inherited forms of heart disease. The private company is based in Pfäffikon, Switzerland, and has additional presence in Massachusetts and other locations. The company's lead preclinical program, DINA-001, is aimed at treating mybpc3-linked cardiomyopathy. Founded in 2019, the CEO of DiNAQOR is Johannes Holzmeister. | Health Technology |
- Stock Market
- Insiders
- Steven Zelenkofske
